Pharma Mar SA (ES:PHM) has released an update.
Pharma Mar S.A. has received a significant payment of $10 million from Janssen Products LP, a subsidiary of Johnson & Johnson, marking a commercial milestone in their license agreement for the cancer treatment drug Yondelis® in the U.S. This milestone underlines the successful collaboration between Pharma Mar and Janssen, enhancing Pharma Mar’s financial standing and reinforcing its position in the biopharmaceutical industry.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
